Treating Multiple Myeloma with T-cell Directed Therapy: Bispecific Antibodies
Recorded on: May 24, 2023
Recorded on: May 24, 2023
Date of expiration: July 20, 2024
Estimated time to complete activity: 0.75 hour
Target Audience
This activity is intended for hematologist-oncologists, fellows, PAs, NPs, nurses, pharmacists, social workers, and other healthcare professionals involved in the care of patients with blood cancer.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain treatment options and provide an overview of the latest developments in therapy for patients with myeloma, focusing on refractory disease
- Interpret the clinical significance of new and emerging data regarding T-cell therapy
- Identify patients who are candidates for bispecific antibody therapy
- Explain the HCP’s role in preparing the patient for therapy, administering treatment, monitoring for and managing side effects
- List education and support resources for patients and caregivers and how to access them
Faculty
Saad Z. Usmani MD, MBA, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY
There is no continuing education credit offered for this activity.
There are no fees for participating in this activity.
Provider
This activity is provided by The Leukemia & Lymphoma Society.
This activity is supported by Janssen Oncology.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.